Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines

Journal of Experimental Medicine

Volumn 183, Issue 4, 1996, Pages 1357-1365

  Mayordomo, Jose I ^a   Loftus, Douglas J ^b   Sakamoto, Hiroshi ^b   De Cesare, Cristina M ^c,d   Appasamy, Pierette M ^c,d   Lotze, Michael T ^a   Storkus, Walter J ^a   Appella, Ettore ^b   DeLeo, Albert B ^c,d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d Department of Pathology ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 4; PROTEIN P53;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; FEMALE; IMMUNIZATION; IMMUNOMODULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SARCOMA; TUMOR SUPPRESSOR GENE;

AMINO ACID SEQUENCE; ANIMALS; BASE SEQUENCE; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; HISTOCOMPATIBILITY ANTIGENS CLASS I; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS; PROTEIN BINDING; SARCOMA, EXPERIMENTAL; TUMOR SUPPRESSOR PROTEIN P53; VACCINATION;

EID: 0029911677     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.183.4.1357     Document Type: Article

References (41)

1. Coulie, P.G., V. Brichard, A. Van Pel, T. Wolfel, J. Schneider, C. Traversari, D.E. DePlaen, C. Lurquin, J.P. Szikora, J.C. Renauld, and T. Boon. 1994. A new gene coding for a differentiation antigen recognized by autologous cytolycic T lymphocytes on HLA-A2 melanomas. J. Exp. Med. 180:35-42.
2. Cox, A.L., J. Skipper, Y. Chen, R.A. Henderson, T.L. Darrow, J. Shabanowitz, V.H. Engelhard, D.G. Hunt, and C.L. Slingluff, Jr. 1994. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science (Wash. DC). 264:716-719.
3. Kawakami, Y., S. Eliyahu, K. Sagaguchi, P.F. Robbins, L. Rivoltini, J.R. Yannelli, E. Appella, and S.A. Rosenberg. 1994. Identification of the immunodominant peptides of MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J. Exp. Med. 180:347-352.
4. + cytotoxic T lymphocytes. J. Exp. Med. 181:363-367.
5. Pardoll, D. 1994. Tumour antigens. A new look for the 1990s. Nature (Lond.). 369:357-358.
6. Houghton, A. 1994. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1-4.
7. Kawakami, Y., S. Eliyahu, C.H. Delgado, P.F. Robbins, K. Sakaguchi, E. Appella, J.R. Yannelli, G.J. Adema, T. Miki, and S.A. Rosenberg. 1994. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc. Natl. Acad. Sci. USA. 91:6458-6462.
8. Steinman, R.M. 1991. The dendritic cell system and its role in immnogenicity. Annu. Rev. Immunol. 9:271-296.
9. + cytotoxic T lymphocytes by dendritic cells. J. Exp. Med. 166:182-194.
10. + cytotoxic T lymphocytes by immunization with syngeneic irradiated HIV-1 envelope derived peptide-pulsed dendritic cells. Int. Immunol. 5:849-857.
11. Grabbe, S., S. Beissert, T. Schwarz, and R.D. Granstein. 1995. Dendritic cells as initiators of tumor immune responses: a possible strategy for tumor immunotherapy? Immunol. Today. 16:116-120.
12. Inaba, K., N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R.M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with GM-CSF. J. Exp. Med. 176:1693-1702.
13. Zorina, T., J.I. Mayordomo, A.B. DeLeo, S. Watkins, and S.T. Ildstad. 1994. Culture of dendritic cells from murine bone marrow supplemented with GM-CSF and TNFα. J. Immunother. 16:247-258.
14. Mayordomo, J.I., T. Zorina, W.J. Storkus, C. Celluzzi, L. Falo, W.M. Kast, S.T. Ildstad, A.B. De Leo, and M.T. Lotze. 1995. Bone marrow-derived dendritic cells pulsed with tumor peptides elicit protective and therapeutic anti-tumor immunity. Nature Med. 1:1297-1302.
15. Zitvogel, L., J.I. Mayordomo, T. Tjandrawan, A.B. DeLeo, M.R. Clarke, M.T. Lotze, and W.J. Storkus. 1995. Therapy of murine tumors with tumor peptide pulsed dendritic cells: dependence on T cells, B7 costimulation, and Th1-associated cytokines. J. Exp. Med. 183:87-98.
16. Celluzzi, C., J.I. Mayordomo, W.J. Storkus, M.T. Lotze, and L. Falo. 1995. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:283-287.
17. Porgador, A., and E. Gilboa. 1995. Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J. Exp. Med 182: 255-260.
18. Romani, N., S. Gruner, D. Brang, E. Kampgen, A. Lenz, B. Trockenbacker, G. Konwalkinka, P.O. Fritsch, R.M. Steinman, and G. Schuler. 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 189:83-95.
19. Sallusto, F., and A. Lanzavecchia. 1994. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colonly-stimulating factor plus mterleukin-4 and down regulated by tumor necrosis factor α. J. Exp. Med. 179:1109-1118.
20. Parmiani, G. 1993. Tumor immunity as autoimmunity: tumor antigens include normal self proteins which stimulate anergic peripheral T cells. Immunol. Today. 14:536-538.
21. Coulie, P.G., F. Lehmann, B. Lethe, J. Herman, C. Lurquin, M. Andrawiss, and T. Boon. 1995 A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. Proc. Natl. Acad. Sci USA. 92:7976-7980.
22. ink4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science (Wash. DC). 269:1281-1284.
23. Hollstein, M., D. Sidransky, B. Vogelstein, and C.C. Harris. 1991. p53 Mutations in human cancers. Science (Wash. DC). 253:49-53.
24. Zeh, H.J. III, G.H. Leder, M.T. Lotze, R.D. Salter, M. Tector, G. Stuber, S. Modrow, and W.J. Storkus. 1993. Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum. Immunol. 39:79-86.
25. Houbiers, J.G.A., H.W. Nijman, S.H. van der Burg, J.W. Dnjfhout, P. Kenemans, C.J.H. van de Velde, A. Brand, F. Momburg, W.M. Kast, and C.J.M. Melief. 1993. In vitro induction of human cytotoxic T lymphocyte responses against peptides of mutant and wild type p53. Eur. J. Immunol. 23: 2072-2077.
26. DeLeo, A.B., G. Jay, E. Appella, G.G. DuBois, L.W. Law, and L.J. Old. 1979. Identification of a transformation-related protein in chemically induced sarcomas and other transformed cells of the mouse. Proc. Natl. Acad. Sci. USA. 76: 2420-2424.
27. Halevy, O., J. Rodel, A. Peled, and M. Oreri. 1991. Frequent p53 mutations in chemically induced murine fibrosarcoma. Oncogene. 6:1593-1600.
28. + T cells. Proc. Natl. Acad. Sci. USA. 91:3171-3175.
29. Noguchi, Y., E.C. Richards, Y.-T. Chen, and L.J. Old. 1995. Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc. Natl. Acad. Sci. USA. 92:3171-3175.
30. DeLeo, A.B., H. Shiku, T. Takahashi, M. John, and L.J. Old. 1977. Cell surface antigens of chemically induced sarcomas of the mouse. I. Murine leukemia virus related antigens and alloantigens on cultured fibroblasts and sarcomas: description of a unique antigen on BALB/c Meth A sarcoma. J. Exp. Med. 146:720-734.
31. Arai, N., D. Nomura, K. Yokota, D. Wolf, E. Brill, O. Shohat, and V. Rotter. 1986. Immunologically distinct p53 molecules generated by alternative splicing. Mol. Cell. Biol. 6: 3232-3239.
32. Widmann, C., P. Romero, J.L. Maryanski, G. Corradin, and D. Valmori. 1992. T helper epitopes enhance the cytotoxic response of mice immunized with MHC class 1-restricted malaria peptides. J. Immunol. Methods. 155:95-99.
33. d class 1 molecule. Eur. J. Immunol. 23:2005-2010.
34. del Guercio, M.F.,J. Sidney, G. Hermanson, C. Perez, H.M. Grey, R.T. Kubo, and A. Sette. 1995. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J. Immunol. 154:685-693.
35. Appasamy, P.M., T.W. Kenniston, Jr., Y. Weng, E.G. Holt, J. Kost, and W.H. Chambers. 1993. Interleukin 7-induced expression of specific T cell receptor gamma variable region genes in murine fetal liver cultures. J. Exp. Med. 178:2201-2206.
36. Zakut-Houri, R., M. Oren, B Bienz, V. Lavie, S. Hazum, and D. Givol. 1983. A single gene and a pseudogene for the cellular tumor antigen p53. Nature (Lond.). 306:594-597.
37. Sette, A., J. Sidney, M.F. del Guercio, S. Southwood, J. Ruppert, C. Dahlberg, H.M. Grey, and R.T. Kubo. 1994. Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol. Immunol. 31:813-822.
38. Ruppert, J., J. Sidney, E. Celis, R.T. Kubo, H.M. Grey, and A. Sette. 1993. Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell. 74:929-937.
39. Kubo, R.T., A. Sette, H.M. Grey, E. Appella, K. Sakaguchi, N.Z. Zhu, D. Arnott, N. Sherman, J. Shabanowitz, and H. Michel. 1994. Definition of specific peptide motifs for four major HLA-A alleles. J. Immunol. 152:3913-3924.
40. Jay, G., A.B. DeLeo, E. Appella, G.C. DuBois, L.W. Law, G. Khoury, and L.J. Old. 1980. A common transformation-related protein in munne sarcomas and leukemias. Cold Spring Harbor Symp. Quant. Biol. 44:659-664.
41. Speiser, D.E., D. Kyburz, U. Subi, H. Hengartner, and R.M. Zinkernagel. 1992. Discrepancy between in vitro measurable and in vivo virus neutralizing cytotoxic T cell reactivities. Low T cell receptor specificity and avidity sufficient for in vitro proliferation and cytotoxicity to peptide-coated target cells but not for in vivo protection. J. Immunol. 149:972-980.